SMOFKABIVEN EXTRA NITROGEN 0.72 G / 100 ML
GLYCINE : 0.72 G / 100 ML ALANINE : 0.92 G / 100 ML CALCIUM CHLORIDE : 0.028 G / 100 ML MAGNESIUM SULFATE : 0.061 G / 100 ML LEUCINE : 0.48 G / 100 ML PHENYLALANINE : 0.33 G / 100 ML TYROSINE : 0.026 G / 100 ML LYSINE (LYSINE ACETATE) : 0.43 G / 100 ML METHIONINE : 0.28 G / 100 ML SERINE : 0.43 G / 100 ML ZINC SULFATE HEPTAHYDRATE : 0.00066 G / 100 ML MEDIUM CHAIN TRIGLYCERIDES (MCT) : 0.87 G / 100 ML VALINE : 0.41 G / 100 ML HISTIDINE : 0.2 G / 100 ML TRYPTOPHAN : 0.13 G / 100 ML OLIVE OIL : 0.72 G / 100 ML POTASSIUM CHLORIDE : 0.23 G / 100 ML DEXTROSE : 8.5 G / 100 ML ISOLEUCINE : 0.33 G / 100 ML FISH OIL : 0.43 G / 100 ML SODIUM GLYCEROPHOSPHATE : 0.23 G / 100 ML SODIUM ACETATE : 0.16 G / 100 ML THREONINE : 0.29 G / 100 ML ARGININE : 0.79 G / 100 ML TAURINE : 0.065 G / 100 ML PROLINE : 0.73 G / 100 ML SOYBEAN OIL : 0.87 G / 100 ML · DIN 02501813 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is SMOFKABIVEN EXTRA NITROGEN?
SMOFKABIVEN EXTRA NITROGEN 0.72 G / 100 ML contains GLYCINE : 0.72 G / 100 ML ALANINE : 0.92 G / 100 ML CALCIUM CHLORIDE : 0.028 G / 100 ML MAGNESIUM SULFATE : 0.061 G / 100 ML LEUCINE : 0.48 G / 100 ML PHENYLALANINE : 0.33 G / 100 ML TYROSINE : 0.026 G / 100 ML LYSINE (LYSINE ACETATE) : 0.43 G / 100 ML METHIONINE : 0.28 G / 100 ML SERINE : 0.43 G / 100 ML ZINC SULFATE HEPTAHYDRATE : 0.00066 G / 100 ML MEDIUM CHAIN TRIGLYCERIDES (MCT) : 0.87 G / 100 ML VALINE : 0.41 G / 100 ML HISTIDINE : 0.2 G / 100 ML TRYPTOPHAN : 0.13 G / 100 ML OLIVE OIL : 0.72 G / 100 ML POTASSIUM CHLORIDE : 0.23 G / 100 ML DEXTROSE : 8.5 G / 100 ML ISOLEUCINE : 0.33 G / 100 ML FISH OIL : 0.43 G / 100 ML SODIUM GLYCEROPHOSPHATE : 0.23 G / 100 ML SODIUM ACETATE : 0.16 G / 100 ML THREONINE : 0.29 G / 100 ML ARGININE : 0.79 G / 100 ML TAURINE : 0.065 G / 100 ML PROLINE : 0.73 G / 100 ML SOYBEAN OIL : 0.87 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02501813, held by FRESENIUS KABI CANADA LTD, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 05-May-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SMOFKABIVEN EXTRA NITROGEN used for?
SmofKabiven [Amino acids with electrolytes, dextrose and lipid injectable emulsion (5.1% & 0.7% / 12.7% / 3.8%); w/v] and SmofKabiven extra Nitrogen [Amino acids with electrolytes, dextrose and lipid injectable emulsion (6.5 % & 0.7% / 8.5% / 2.9%); w/v] are indicated for intravenous infusion into a central vein as parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02501813 |
|---|---|
| Brand name | SMOFKABIVEN EXTRA NITROGEN |
| Generic / active ingredient | GLYCINE : 0.72 G / 100 ML ALANINE : 0.92 G / 100 ML CALCIUM CHLORIDE : 0.028 G / 100 ML MAGNESIUM SULFATE : 0.061 G / 100 ML LEUCINE : 0.48 G / 100 ML PHENYLALANINE : 0.33 G / 100 ML TYROSINE : 0.026 G / 100 ML LYSINE (LYSINE ACETATE) : 0.43 G / 100 ML METHIONINE : 0.28 G / 100 ML SERINE : 0.43 G / 100 ML ZINC SULFATE HEPTAHYDRATE : 0.00066 G / 100 ML MEDIUM CHAIN TRIGLYCERIDES (MCT) : 0.87 G / 100 ML VALINE : 0.41 G / 100 ML HISTIDINE : 0.2 G / 100 ML TRYPTOPHAN : 0.13 G / 100 ML OLIVE OIL : 0.72 G / 100 ML POTASSIUM CHLORIDE : 0.23 G / 100 ML DEXTROSE : 8.5 G / 100 ML ISOLEUCINE : 0.33 G / 100 ML FISH OIL : 0.43 G / 100 ML SODIUM GLYCEROPHOSPHATE : 0.23 G / 100 ML SODIUM ACETATE : 0.16 G / 100 ML THREONINE : 0.29 G / 100 ML ARGININE : 0.79 G / 100 ML TAURINE : 0.065 G / 100 ML PROLINE : 0.73 G / 100 ML SOYBEAN OIL : 0.87 G / 100 ML |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 0.72 G / 100 ML |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA10 COMBINATIONS |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-May-2021 |
| Original market date | 2022-08-01 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code B05BA10 COMBINATIONS. 22 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498456 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013886 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02046709 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498464 |
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013940 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498448 |
| CLINIMIX E | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013967 |
| CLINIMIX E | 261 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498413 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014076 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.